Stocks: Real-time U.S. stock quotes reflect trades reported through ... Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange ...

In a report released today, Andy Hsieh from William Blair maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The company’s shares closed today at $26.61.

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.61, representing a +1.88% change from its previous close.

Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Viking Therapeutics stock is down 52% over the trailing-12-month period. However, many Wall Street analysts remain unashamedly bullish on the company. Viking's average price target of $99.29 ...

Viking Therapeutics, Inc. (NASDAQ ... Viking's market cap of $3.19b prices in some pipeline optimism, but it still is far smaller than say Eli Lilly at $679b. Successful trial completion and ...

Following the release of its earnings report, Viking Therapeutics' stock price experienced a surge, climbing as much as 0%. This positive market response leaves some investors questioning if ...

Analysts expect this obesity drug stock to soar 35% over the next 12 ... The Motley Fool recommends Novo Nordisk, Roche Holding, and Viking Therapeutics. The Motley Fool has a disclosure policy.

Viking Therapeutics has a promising pipeline candidate ... Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns.

Viking Therapeutics(NASDAQ ... was a winning stock this week. Over the course of the past five trading days, its price rose by almost 18%, according to data compiled by S&P Global Market Intelligence.